摘要
目的探讨IL-2+IL-15共同刺激CIK(Cytokine induced killer cell)过继性免疫治疗联合化疗对结直肠癌的疗效及安全性.方法选取在昆明市延安医院医院普外1科治疗的110例结直肠患者,55例CIK联合化疗组,55例行单纯化疗组,评价2组患者治疗后免疫功能、疗效、毒副反应和生活质量.结果 IL-2+IL-15刺激的CIK细胞较单纯IL-2刺激细胞具有较强的细胞毒性和较快的增殖效率;CIK联合化疗组治疗前后外周血T细胞亚群均有升高,但差异无统计学意义(P>0.05),化疗组治疗后外周血中CD3+、CD4+、CD8+、CD16+CD56+、NKp46、NKG2D、CD11b、CD27细胞比例较治疗前下降;联合免疫治疗组与单纯化疗组治疗后Kamofsky评分总提高率分别为87.3%与69.1%,2组比较差异有统计学意义(P<0.05).结论 IL-2+IL-15刺激CIK过继性免疫治疗联合化疗可以明显改善结直肠癌患者的免疫功能,提高总体疗效,减轻化疗不良反应,延长无进展生存,改善患者生活质量.
Objective To evaluate the efficacy and safety of IL-2+IL-15 costimulated CIK adoptive immunotherapy combined with chemotherapy for colorectal cancer. Methods 110 colorectal cancer patients were selected from the department of general surgery in Yan'an Hospital. 55 cases were treated with CIK combined with chemotherapy, and the other 55 cases were treated with simple chemotherapy. The immune function, efficacy,toxicity and quality of life after treatment in each group were evaluated. Results The stronger cytotoxicity and rapid proliferation efficiency were found in IL-12+IL-15 stimulated CIK cells than simple IL-2 stimulated CIK cells. T cell subsets in peripheral blood increased in CIK combined with chemotherapy group before and after treatment,but there were no significant changes(P〉0.05). The ratios of CD3+,CD4+,CD8+,CD16+CD56+,NKp46,NKG2 D, CD11 b, CD27 cells in peripheral blood decreased after treatment in chemotherapy group. The kamofsky score was 87.3% and 69.3% in combined immune therapy group and simple chemotherapy group, respectively,and there was a significant difference between two groups(P〈0.05). Conclusion IL-2+IL-15 costimulated CIK adoptive immunotherapy combined with chemical therapy can significantly improve the immune function of patients with colorectal cancer, improve the overall efficacy, reduce the adverse reactions of chemotherapy, prolong progression-free survival,and improve patients' quality of life.
出处
《昆明医科大学学报》
CAS
2014年第11期97-101,共5页
Journal of Kunming Medical University
基金
云南省科技厅-昆明医科大学联合专项基金资助项目(2010CD211)